March 8, 2025 - 23:35

Amid limited access to pediatric dermatologists nationwide, pediatric patients of color with atopic dermatitis (AD) are particularly affected by social determinants of health, further impacting their outcomes. Research indicates that various factors, including socioeconomic status, access to healthcare, and environmental conditions, play a crucial role in the management and treatment of AD in these communities.
Children of color often experience barriers such as inadequate healthcare access, lack of insurance, and transportation challenges, which can hinder timely and effective treatment. These obstacles not only exacerbate the severity of the condition but also lead to a cycle of poor health outcomes and increased healthcare costs.
Addressing these social determinants is essential for improving the quality of care for pediatric patients with AD. Initiatives aimed at increasing awareness, enhancing access to specialists, and providing community support can significantly impact the management of atopic dermatitis in these vulnerable populations. By prioritizing these factors, healthcare systems can work towards achieving equitable health outcomes for all children, regardless of their background.
June 25, 2026 - 03:04
Houston Methodist receives $110M donation, largest in health system’s historyHouston Methodist has received a $110 million gift from The Brockman Medical Research Foundation, marking the largest single donation in the health system`s history. The funds are designated to...
June 24, 2026 - 07:18
Reproductive Health and Constitutionalism in Latin America: A Research AgendaVeronica Undurraga, a professor at the Faculty of Law of Universidad Adolfo Ibanez, has put forward a new research agenda examining the intersection of reproductive health and constitutionalism...
June 23, 2026 - 21:10
Trump administration charges 455 people, including doctors, with $6.5 billion in healthcare fraudThe Justice Department announced charges on Tuesday against 455 individuals, including dozens of doctors, for their alleged roles in healthcare fraud schemes and opioid abuse totaling 6.5 billion...
June 23, 2026 - 04:50
Federal health agencies unveil plan to speed up phase 1 clinical trials by 6 to 12 monthsAs the biotech industry gathers in San Diego for the BIO International Convention, the Department of Health and Human Services has released a series of initiatives aimed at accelerating early-stage...